Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Jensen Investment Adam Calamar, Kurt Havnaer, Tyra Pratt | “The manager liquidated HOLX, a women's healthcare medical technology firm. The exit was prompted by limited remaining upside in the stock price ahead of its acquisition by private equity firms Blackstone and TPG.” | BEAR | Q1 2026 Apr 29, 2026 | View Pitch |
The Gabelli ABC Fund Mario J. Gabelli, CFA, Willis Brucker | “Hologic Inc. (3.3%) is a manufacturer of medical imaging systems and diagnostic products focused on women's health. Hologic agreed to be acquired by Blackstone and TPG for $76.00 cash per share, valuing the transaction at approximately $18 billion. The transaction is subject to shareholder and regulatory approvals and is expected to close in the second quarter of 2026. We believe the agreed price reflects the strength of Hologic's franchise in diagnostics and breast health imaging. The deal underscores private equity appetite for high-margin, cash-generative healthcare assets. BSD Analysis: Hologic is diagnostics and women's health infrastructure that looks cyclical only because COVID temporarily distorted the base. Core franchises in breast health, molecular diagnostics, and surgical products are embedded in screening guidelines and clinical workflows. Investors fixate on post-pandemic revenue normalization and miss the durability of recurring consumables. Pricing power is subtle but real because outcomes and reliability matter more than unit cost. Installed base economics drive service and reagent pull-through for years after system placement. Capital allocation has been pragmatic rather than promotional. This is healthcare plumbing with a focused niche and steady cash generation.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
ACATIS Investment Dr. Hendrik Leber | “The company continues to face challenges in the form of geopolitical uncertainties (e.g. higher US tariffs) as well as overall weaker global demand, particularly in China and South Korea. As a result, it was forced to lower its profit forecasts. We sold the stock to reduce the share of medical technology companies in our strictly sustainable equity fund. BSD Analysis: Hologic opened fiscal 2026 with a measured performance, reporting first-quarter revenue of $1.02 billion and a basic EPS of $0.80. While the company maintains a solid net margin of approximately 13.2%, recent quarters have been characterized by significant one-off losses, including a $346.8 million drag that has weighed on overall earnings quality.Despite these fluctuations, the core business remains profitable, and forward-looking estimates point to an earnings growth trajectory of roughly 13.7% per year as the firm navigates a post-pandemic reset. Management is focused on stabilizing margins and proving that recent profit volatility is a transitory feature rather than a structural headwind. With a consistent ability to generate revenue above $1 billion per quarter, Hologic offers a defensive healthcare play with a clear path toward earnings normalization in a stabilizing diagnostic market.” | BULL | Q3 2025 Oct 6, 2025 | View Pitch |
The Sound Shore Fund Harry Burn, III; John P. DeGulis; T. Gibbs Kane, Jr. | “Similarly, we added to Hologic, Inc., a medical technology supplier primarily focused on diagnostics and improving women's health. Rumors of a possible private equity buyout offer for the company surfaced in late May, which highlights the value within parts of the healthcare sector and Hologic's particularly compelling valuation around 14 times earnings. BSD Analysis: Hologic is a high-quality, focused MedTech specialist whose stock is a conviction bet on the non-cyclical, accelerating demand for women's health diagnostics. The core moat is its dominance in three high-margin segments: Diagnostics, Breast Health, and GYN Surgical. The company is driving superior growth through its Molecular Diagnostics and Breast Health divisions, which are fueled by the adoption of high-value assays and 3D Mammography systems. This focus on non-cyclical, high-value testing ensures consistent revenue growth and strong margins. Hologic is a high-quality compounder leveraging its market leadership to expand its installed base and drive recurring revenue from high-margin consumables.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
